Psychiatria pre prax 1/2017

Paliperidone palmitate for once a three month application. Basic characteristics with emphasis on clinical use

After the availability of paliperidone palmitate long acting injection with once a month administration, the new drug form with the same active substance, but with once a three month administration, was approved. Pharmacokinetics characteristic and efficacy of the new drug was determined in pre-registration studies and recommended doses when switching from one month to three months form were defined. The new drug may be effective in further reduction of the risk of relapses caused by nonadherence and may significantly reduce the burden and discomfort connected with depot medication. The aim of the article is to provide basic information on characteristics of paliperidone palmitate for three-month intervals of administration and to describe the mode of application in clinical practice.

Keywords: paliperidone palmitate, long-term treatment, schizophrenia